🔗 Share this article

While America proceeds with unprecedented adjustments to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines throughout the global health crisis and has concentrated on possible deaths following COVID-19 vaccination in her recent tenure at the FDA.

Scheduled Changes to Pediatric Immunization Schedule

Health officials planned to unveil sweeping revisions to the pediatric vaccine schedule recently, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of step with many the world with little proof for improved outcomes. The planned update has been pushed back until the next year.

In place of Vinay Prasad, Høeg is listed to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the office this year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing certain pediatric shot schedules in the US in order to be more like Denmark, a society with universal health coverage and a population roughly the size of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – usually the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Expertise

Dr. Høeg has little discernible track record in medication creation, approval processes or leadership, which has been customary for past leaders of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the CDER, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a large organization. She has no expertise in drug approvals.”

Former heads of the center would “understand legal statutes and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that former directors who headed the center have had.”

The drug center has an vast workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and other areas, and each of these need to be looked after,” Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the job, which oversees over 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” the former official concluded.

Response and Disputed Initiatives

In response to concerns about Høeg’s credentials and whether this assignment indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “questions stem from flawed assumptions”.

“Her experience matches the functions of her job,” the representative said, noting the period Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's new expedited review system, a disputed rapid drug-approval program that reportedly troubled her predecessors. “By what process are these medications being chosen for this voucher program? Who takes the choices?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards laxer rules of most medications, aside from shots.”

Documented History on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if problematic, history, critics have noted. She released a analysis using unconfirmed public submissions to estimate the rate of heart inflammation after Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the new administration encompassed altering guidelines for new vaccines and ending “optional” immunizations, she said post-election on a online show. At the FDA, Høeg has reportedly suggested excluding adolescent males from receiving COVID-19 vaccinations.

“She is an complete dogmatist who starts off with her beliefs and works backwards to retrofit the science in a very disingenuous, dishonest fashion,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|